Emerging therapies for Parkinson's disease

Current Opinion in Neurology

Volumn 25, Issue 4, 2012, Pages 448-459

  Poewe, Werner ^a   Mahlknecht, Philipp ^a   Jankovic, Joseph ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Drug delivery; Experimental therapies; Gene therapy; Neuroprotection; Nondopaminergic drug

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; ADX 48621; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; APOMORPHINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CVT 301; DIPRAGLURANT; ENTACAPONE; FIPAMEZOLE; ISTRADEFYLLINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEBICAPONE; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PARDOPRUNOX; PERAMPANEL; PICLOZOTAN; PLACEBO; PRELADENANT; PYM 50028; SAFINAMIDE; SARIZOTAN; SEROTONIN AGONIST; TOZADENANT; UNCLASSIFIED DRUG; VR 040; XP 21279;

CELL THERAPY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG RESEARCH; DYSKINESIA; GENE THERAPY; HUMAN; MOTOR CONTROL; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK ASSESSMENT;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE;

EID: 84863699012     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283542fde     Document Type: Review

References (99)

1. Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol 2010; 257 (Suppl 2):S268-S275.
2. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5:677-687. (Pubitemid 44081890)
3. Morelli M, Carta AR,Kachroo A,SchwarzschildMA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res 2010; 183:183-208.
4. Poewe W. Parkinson disease: treatment of the nonmotor symptoms of Parkinson disease. Nat Rev Neurol 2010; 6:417-418.
5. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol. 2012. doi:10.1111//j.1468-1331. [Epub ahead of print]
6. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31:63-73. (Pubitemid 351489331)
7. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64:216-223.
8. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011; 26:2246-2252.
9. Hauser RA. Future treatments for Parkinson's disease: surfing the PD pipeline. Int J Neurosci 2011; 121 (Suppl 2):53-62.
10. Pahwa R, Ellenbogen A, Jankovic J, et al. Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naive early Parkinson's disease (APEX-PD trial). Mov Disord 2011; 26 (Suppl 2):S137-S1137.
11. LeWitt PA, Ellenbogen A, Chen D, et al. Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol 2012 [Epub ahead of print].
12. Grosset KA, Morgan F. Grosset D, for the VRIASG. Inhaled apomorphine (VR040) for 'off' periods inParkinson's Disease.MovDisord2011;26(Suppl 2): S129-S1129.
13. Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 2012. [Epub ahead of print]
14. Sampaio C, Bronzova J, Hauser RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011; 26:1464-1476.
15. Hauser RA, Bronzova J, Sampaio C, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur Neurol 2009; 62:40-48.
16. DuToit J, Coetzee C, Grant T, et al. Aplindore, a partial dopamine agonist, improves motor aspects of Parkinson's disease in a 14-day escalating dose paradigm. Mov Disord 2009; 24(Suppl. 1):S263.
17. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27:58-62. (Pubitemid 38569176)
18. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22:179-186. (Pubitemid 46374758)
19. Sage JI, Hauser RA, Cordon ME, et al. Pilot study of the efficacy and safety of piclozotan in Parkinson's disease patients with L-dopa induced motor complications. Mov Disord 2009; 24(Suppl. 1):S277.
20. Eggert K, Squillacote D, Barone P, et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010; 25:896-905.
21. Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing 'off' time in Parkinson's disease. Mov Disord 2012; 27:284-288.
22. Rascol O, Barone P, Behari M, et al. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012; 35:15-20.
23. Dimitrova TD, Bara-Jimenez W, Savola JM, et al. Alpha-2 adrenergic antagonist effects in Parkinson's disease. Mov Disord 2009; 24 (Suppl. 1):S261-S1261.
24. LeWitt PA, Hauser RA, Lu M, et al. Fipamezole in the treatment of dyskinesia in advanced Parkinson's disease (FJORD study). Mov Disord 2010; 25 (Suppl 2):S300-S1300.
25. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopainduced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011; 26:1243-1250.
26. Stocchi F, Destee A, Hattori N, et al. A 13-week, double-blind, placebocontrolled study of AFQ056, a metabotropic glutamate receptor 5 antagonist in Parkinson's disease patients with moderate-to-severe L-dopa induced dyskinesias. Mov Disord 2011; 24(Suppl. 1):6-7; Late Breaking Abstract, Abstract no. LB 12.
27. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63:746-748. (Pubitemid 39100843)
28. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebocontrolled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27:106-112.
29. Borgohain R, Szasz J, Stanzione P, et al. First 2-year, controlled study to assess safinamide as add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2011; 26 (Suppl 2):S120.
30. Borgohain R, Mehta NA, Bajenaru OA, et al. Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease. Mov Disord 2010; 25 (Suppl 2):S291-S1291.
31. Meshram CM, Bhatt M, Chirileanu D, et al. Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with midlate Parkinson's disease. Mov Disord 2010; 25 (Suppl 2):S302-S1302.
32. Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61:293-296. (Pubitemid 36975954)
33. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advancedPD.Neurology 2003; 61:297-303. (Pubitemid 36975955)
34. LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a doubleblind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008; 63:295-302. (Pubitemid 351499859)
35. Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008; 70:2233-2240.
36. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23:2177-2185.
37. Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord 2010; 25:1437-1443.
38. Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012; 18:178-184.
39. Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010; 16:16-20.
40. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011; 10:221-229.
41. Black KJ, Campbell MD, Dickerson W, et al. A randomized, double-blind, placebo-controlled cross-over trial of the adenosine 2A antagonist SYN115 in Parkinson's Disease. Neurology 2010; 74 (Suppl 2):A317-A317.
42. Black KJ, Koller JM, Campbell MC, et al. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 2010; 30:16284-16292.
43. Ferreira JJ, Rascol O, Poewe W, et al. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci Ther 2010; 16:337-347.
44. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66:1824-1829. (Pubitemid 44049810)
45. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9:1164-1172.
46. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008; 7:400-408.
47. Stover NP, Bakay RA, Subramanian T, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch Neurol 2005; 62:1833-1837. (Pubitemid 41785076)
48. Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2011; 10:509-519.
49. Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 2010; 155:62-70.
50. Muramatsu S, Fujimoto K, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010; 18:1731-1735.
51. Jarraya B, Lepetit B, Ralph S, et al. A phase I clinical trial on the safety and efficacy of ProSavin1 a dopamine replacement gene therapy for Parkinson's disease (PD): an interim report. Mov Disord 2010; 25(Suppl. 2):S267.
52. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369:2097-2105. (Pubitemid 46935946)
53. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10:309-319.
54. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the nonmotor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3):S42-S80.
55. Elahi B, Chen R. Effect of transcranial magnetic stimulation on Parkinson motor function: systematic review of controlled clinical trials. Mov Disord 2009; 24:357-363.
56. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 2010; 75:1912-1919.
57. Pitts T, Bolser D, Rosenbek J, et al. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest 2009; 135:1301-1308.
58. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010; 159:495-501.
59. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord 2010; 25 (Suppl 1):S63-S70.
60. Quik M, Huang LZ, Parameswaran N, et al. Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 2009; 78:677-685.
61. Mandel SA, Amit T, Weinreb O, et al. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther 2008; 14:352-365.
62. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011; 118:473-477.
63. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann NY Acad Sci 2008; 1147:395-412.
64. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34:1131-1136. (Pubitemid 14068582)
65. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984; 107 (Pt 2):487-506. (Pubitemid 14108832)
66. Olanow CW, Chatamra K, Benesh J, et al. Design of a randomized, doubleblind, double-dummy, placebo-controlled study of levodopa-carbidopa intestinal gel in patients currently receiving optimized treatment for advanced Parkinson's disease. Mov Disord 2011; 26 (Suppl 2):S137-S1137.
67. LeWitt PA. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology 1992; 42:29-32.
68. Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986; 9:430-439. (Pubitemid 17196758)
69. Koller WC, Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology 1994; 44 (7 Suppl 6):S23-S28.
70. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999; 53:1012-1019. (Pubitemid 29442117)
71. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93:14-20. (Pubitemid 26035679)
72. Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53:3396-3411.
73. Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res 2010; 183:209-233.
74. Cenci MA, Lindgren HS. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007; 17:665-671.
75. Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl 3): S2-S41.
76. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010; 25:1357-1363.
77. Gregoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011; 17:270-276.
78. Girard F, Keywood C, Poli SP, Mutel V. Antiparkinsonian effects of ADX48621 a mGluR5 negative allosteric modulator, in the rat haloperidol induced catalepsy model. Mov Disord 2010; 25(Suppl. 2):S282.
79. Hill MP, Girard F, Keywood C, et al. ADX48621, a novel mGlu5 negative allosteric modulator alleviates L-DOPA-induced chorea and dystonia in the MPTP lesioned macaque model of Parkinson's disease. Mov Disord 2010; 25(Suppl. 2):S281.
80. Fox SH, Brotchie JM, Lang AE. Nondopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008; 7:927-938.
81. Savola JM, Hill M, Engstrom M, et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003; 18:872-883. (Pubitemid 37021161)
82. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011; 95:163-212.
83. Rylander D, Parent M, O'Sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010; 68:619-628.
84. Langston JW, Quik M, Petzinger G, et al. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000; 47 (4 Suppl 1): S79-S89. (Pubitemid 30192013)
85. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57:1829-1834. (Pubitemid 33096691)
86. Tani Y, Ogata A, Koyama M, Inoue T. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. Eur J Pharmacol 2010; 649:218-223.
87. Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther 2011; 339:2-8.
88. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008; 23:700-707.
89. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247:574-577.
90. Spencer DD, Robbins RJ, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 1992; 327:1541-1548.
91. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 2012; 10:1.
92. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710-719. (Pubitemid 32204988)
93. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54:403-414. (Pubitemid 37072046)
94. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. NatMed 2008; 14:504-506. (Pubitemid 351655212)
95. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14:501-503. (Pubitemid 351655211)
96. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011; 26(1):27-36
97. Gold M, Lorenzl S, Stewart AJ, et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012; 8:85-93.
98. Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009; 24:647-654.
99. Quik M, Campos C, Parameswaran N, et al. Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage. J Mol Neurosci 2010; 40:105-113.